Pomona Ricerca

Executive Summary

Pomona Ricerca is a private Italian biotech company established in 1998, dedicated to the discovery and development of broadly neutralizing monoclonal antibodies (mAbs) for critical infectious diseases. Based in Milan, the company combines internal therapeutic and vaccine R&D with commercial services including custom antibody generation and recombinant protein distribution. With over two decades of experience, Pomona Ricerca aims to provide universal solutions against pathogens such as HIV, influenza, and emerging viruses, leveraging its expertise in antibody engineering and neutralization mechanisms. The company's pipeline, though undisclosed, is expected to target conserved epitopes to achieve broad coverage across viral strains. As a pre-clinical stage entity, Pomona Ricerca's near-term focus is on advancing its lead antibody candidates through in vivo efficacy studies and IND-enabling toxicology. The company may also seek strategic partnerships or licensing agreements with larger biopharma firms to accelerate clinical development. Given its long-standing presence and specialization in a high-demand area, Pomona Ricerca is positioned to capitalize on the growing need for broad-spectrum antivirals. However, the lack of publicly disclosed pipeline details and recent funding rounds introduces uncertainty regarding its near-term milestones.

Upcoming Catalysts (preview)

• Q2 2027Lead antibody candidate enters IND-enabling studies50% success
• Q4 2026Partnership or licensing deal with a major pharma company30% success
• Q3 2026Receipt of non-dilutive grant funding for infectious disease research60% success